Patents by Inventor Mary Osbakken

Mary Osbakken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220193383
    Abstract: The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation. Integumental perturbation can be used in combination with other treatments for promoting hair growth. The invention provides devices for integumental perturbation for promoting hair growth, and provides pharmaceutical compositions for use in combination with integumental perturbation for promoting hair growth.
    Type: Application
    Filed: September 24, 2021
    Publication date: June 23, 2022
    Applicant: FOLLICA, INC.
    Inventors: Shikha P. Barman, William D. Ju, Scott C. Kellogg, Stephen M. Prouty, Eric Schweiger, Seth Lederman, Mary Osbakken, Alan D. Schinazi
  • Patent number: 11207511
    Abstract: The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation. Integumental perturbation can be used in combination with other treatments for promoting hair growth. The invention provides devices for integumental perturbation for promoting hair growth, and provides pharmaceutical compositions for use in combination with integumental perturbation for promoting hair growth.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: December 28, 2021
    Assignee: Follica, Inc.
    Inventors: Shikha P. Barman, William D. Ju, Scott C. Kellogg, Stephen M. Prouty, Eric Schweiger, Seth Lederman, Mary Osbakken, Alan D. Schinazi
  • Publication number: 20190381296
    Abstract: The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation. Integumental perturbation can be used in combination with other treatments for promoting hair growth. The invention provides devices for integumental perturbation for promoting hair growth, and provides pharmaceutical compositions for use in combination with integumental perturbation for promoting hair growth.
    Type: Application
    Filed: October 18, 2018
    Publication date: December 19, 2019
    Inventors: Shikha P. Barman, William D. Ju, Scott C. Kellogg, Stephen M. Prouty, Eric Schweiger, Seth Lederman, Mary Osbakken, Alan D. Schinazi
  • Publication number: 20140079686
    Abstract: The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation. Integumental perturbation can be used in combination with other treatments for promoting hair growth. The invention provides devices for integumental perturbation for promoting hair growth, and provides pharmaceutical compositions for use in combination with integumental perturbation for promoting hair growth.
    Type: Application
    Filed: December 6, 2011
    Publication date: March 20, 2014
    Inventors: Shikha P. Barman, William D. Ju, Scott C. Kellogg, Stephen M. Prouty, Eric Schweiger, Seth Lederman, Mary Osbakken, Alan D. Schinazi
  • Publication number: 20120039954
    Abstract: A method of treating insomnia comprising administering to a subject a formulation including zaleplon, wherein the formulation is adapted to release the zaleplon after a lag time of at least about one hour after administration of the formulation, and during which substantially no drug substance is released; provide a time of peak plasma concentration of about 3 hours to about 6 hours after administration; provide an elimination half-life after the time of peak plasma concentration of about 0.5 hours to about 0.3 hours; and provide an area under the curve of about 70 ng·h/mL to about 90 ng·h/mL.
    Type: Application
    Filed: December 15, 2009
    Publication date: February 16, 2012
    Applicant: SOMNUS THERAPEUTICS, INC.
    Inventors: Gary Cupit, Anne McCormick, Mary Osbakken, Christine Blumhardt